Effectiveness and safety of antiretroviral treatment in pre- and postmenopausal women living with HIV in a multicentre cohort.

IF 1.3 4区医学 Q4 INFECTIOUS DISEASES

Antiviral Therapy Pub Date : 2020-01-01 DOI:10.3851/IMP3380

Belén Alejos, Inés Suárez-García, Jose Ignacio Bernardino, José Ramón Blanco, Maria Peñaranda, Azucena Bautista, Félix Gutiérrez, Inma Jarrín, Victoria Hernando

{"title":"Effectiveness and safety of antiretroviral treatment in pre- and postmenopausal women living with HIV in a multicentre cohort.","authors":"Belén Alejos, Inés Suárez-García, Jose Ignacio Bernardino, José Ramón Blanco, Maria Peñaranda, Azucena Bautista, Félix Gutiérrez, Inma Jarrín, Victoria Hernando","doi":"10.3851/IMP3380","DOIUrl":null,"url":null,"abstract":"Background: To compare effectiveness and safety of initial antiretroviral therapy (ART) among premenopausal and postmenopausal women living with HIV aged 45-60 years from the cohort of the Spanish HIV/AIDS Research Network (CoRIS) who initiated ART between 2004 and 2015.Methods: Multivariable regression models were used to compare post- versus premenopausal women regarding viral suppression (≤50 copies/ml), change in CD4+ T-cell count and time to treatment change (TC) at 48 and 96 weeks after ART initiation.Results: Among 230 women, 154 (67%) were premenopausal at ART initiation. The most frequent initial regimen was tenofovir disoproxil fumarate/emtricitabine/efavirenz prescribed in 49 (32%) premenopausal and 22 (29%) postmenopausal women. The proportion of TC was 35.7% and 30.3% at 48 weeks and 51.3% and 47.4% at 96 weeks, for pre- and postmenopausal women, respectively. There were no significant differences in CD4+ T-cell count changes from ART initiation, viral load suppression, time to TC or reason for TC between both groups. The main reason for TC was occurrence of an adverse event, followed by simplification, in both groups.Conclusions: ART effectiveness and safety did not differ significantly between pre- and postmenopausal women.","PeriodicalId":8364,"journal":{"name":"Antiviral Therapy","volume":"25 6","pages":"335-340"},"PeriodicalIF":1.3000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Antiviral Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3851/IMP3380","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 2

Abstract

Background: To compare effectiveness and safety of initial antiretroviral therapy (ART) among premenopausal and postmenopausal women living with HIV aged 45-60 years from the cohort of the Spanish HIV/AIDS Research Network (CoRIS) who initiated ART between 2004 and 2015.

Methods: Multivariable regression models were used to compare post- versus premenopausal women regarding viral suppression (≤50 copies/ml), change in CD4⁺ T-cell count and time to treatment change (TC) at 48 and 96 weeks after ART initiation.

Results: Among 230 women, 154 (67%) were premenopausal at ART initiation. The most frequent initial regimen was tenofovir disoproxil fumarate/emtricitabine/efavirenz prescribed in 49 (32%) premenopausal and 22 (29%) postmenopausal women. The proportion of TC was 35.7% and 30.3% at 48 weeks and 51.3% and 47.4% at 96 weeks, for pre- and postmenopausal women, respectively. There were no significant differences in CD4⁺ T-cell count changes from ART initiation, viral load suppression, time to TC or reason for TC between both groups. The main reason for TC was occurrence of an adverse event, followed by simplification, in both groups.

Conclusions: ART effectiveness and safety did not differ significantly between pre- and postmenopausal women.

查看原文本刊更多论文

在多中心队列中，抗逆转录病毒治疗对绝经前和绝经后感染艾滋病毒的妇女的有效性和安全性。

背景:比较2004年至2015年间西班牙HIV/AIDS研究网络(CoRIS)队列中45-60岁的绝经前和绝经后感染HIV的妇女接受初始抗逆转录病毒治疗(ART)的有效性和安全性。方法:采用多变量回归模型比较绝经后和绝经前妇女在抗逆转录病毒治疗开始后48周和96周的病毒抑制(≤50拷贝/ml)、CD4+ t细胞计数变化和治疗改变时间(TC)。结果:在230名妇女中，154名(67%)在ART开始时处于绝经前。49名(32%)绝经前妇女和22名(29%)绝经后妇女最常见的初始方案是富马酸替诺福韦二吡酯/恩曲他滨/依非韦伦。绝经前和绝经后妇女的TC比例在48周时分别为35.7%和30.3%，96周时分别为51.3%和47.4%。两组在ART起始、病毒载量抑制、TC时间及TC原因的CD4+ t细胞计数变化无显著差异。两组患者发生TC的主要原因是不良事件的发生，其次是简化。结论:抗逆转录病毒治疗的有效性和安全性在绝经前和绝经后妇女之间无显著差异。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Antiviral Therapy 医学-病毒学

CiteScore

2.60

自引率

8.30%

发文量

审稿时长

4-8 weeks

期刊介绍： Antiviral Therapy (an official publication of the International Society of Antiviral Research) is an international, peer-reviewed journal devoted to publishing articles on the clinical development and use of antiviral agents and vaccines, and the treatment of all viral diseases. Antiviral Therapy is one of the leading journals in virology and infectious diseases. The journal is comprehensive, and publishes articles concerning all clinical aspects of antiviral therapy. It features editorials, original research papers, specially commissioned review articles, letters and book reviews. The journal is aimed at physicians and specialists interested in clinical and basic research.